ENXTBR:UCB

Stock Analysis Report

Executive Summary

UCB SA, a biopharmaceutical company, researches, develops, manufactures, sells, and distributes biopharmaceutical solutions for people living with neurology and immunology conditions.

Snowflake

Fundamentals

Flawless balance sheet average dividend payer.


Similar Companies

Share Price & News

How has UCB's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-1.7%

ENXTBR:UCB

-1.7%

BE Pharmaceuticals

1.3%

BE Market


1 Year Return

-16.7%

ENXTBR:UCB

-16.8%

BE Pharmaceuticals

2.5%

BE Market

UCB matched the Pharmaceuticals industry (-16.8%) over the past year.

UCB underperformed the Market in Belgium which returned 2.5% over the past year.


Share holder returns

UCBIndustryMarket
7 Day-1.7%-1.7%1.3%
30 Day-4.5%-5.6%2.0%
90 Day-9.9%1.1%5.5%
1 Year-15.7%-16.7%-15.9%-16.8%4.8%2.5%
3 Year-6.9%-10.3%24.1%10.2%-3.6%-10.5%
5 Year-2.9%-8.7%24.8%4.3%23.2%7.9%

Price Volatility Vs. Market

How volatile is UCB's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is UCB undervalued based on future cash flows and its price relative to the stock market?

13%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

UCB's share price is below the future cash flow value, but not at a moderate discount (< 20%).

UCB's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

UCB is good value based on earnings compared to the Europe Pharmaceuticals industry average.

UCB is overvalued based on earnings compared to the Belgium market.


Price Based on Expected Growth

UCB is poor value based on expected growth next year.


Price Based on Value of Assets

UCB is good value based on assets compared to the Europe Pharmaceuticals industry average.


Next Steps

Future Growth

How is UCB expected to perform in the next 1 to 3 years based on estimates from 12 analysts?

6.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

UCB's revenue is expected to grow by 0.7% yearly, however this is not considered high growth (20% yearly).

UCB's earnings are expected to grow by 6.9% yearly, however this is not considered high growth (20% yearly).

UCB's revenue growth is positive but not above the Belgium market average.

UCB's earnings growth is expected to exceed the Belgium market average.

UCB's earnings growth is expected to exceed the low risk savings rate of 0.8%.


Earnings per Share Growth Estimates


Future Return on Equity

UCB is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).


Next Steps

Past Performance

How has UCB performed over the past 5 years?

33.5%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

UCB has delivered over 20% year on year earnings growth in the past 5 years.

UCB's 1-year earnings growth is negative, it can't be compared to the 5-year average.

UCB's 1-year earnings growth is negative, it can't be compared to the Europe Pharmaceuticals industry average.


Return on Equity

UCB has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

UCB used its assets more efficiently than the Europe Pharmaceuticals industry average last year based on Return on Assets.


Return on Capital Employed

UCB has significantly improved its use of capital last year versus 3 years ago (Return on Capital Employed).


Next Steps

Financial Health

How is UCB's financial position?


Financial Position Analysis

UCB is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

UCB's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

UCB's level of debt (19.7%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (50.5% vs 19.7% today).

Debt is well covered by operating cash flow (74.5%, greater than 20% of total debt).

Interest payments on debt are well covered by earnings (EBIT is 19.4x coverage).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 2.2x debt.


Next Steps

Dividend

What is UCB's current dividend yield, its reliability and sustainability?

1.97%

Expected Dividend Yield


Dividend Yield and Payments Analysis

UCB's pays a lower dividend yield than the bottom 25% of dividend payers in Belgium (2.27%).

UCB's dividend is below the markets top 25% of dividend payers in Belgium (4.55%).

Dividends per share have been stable in the past 10 years.

Dividends per share have increased over the past 10 years.


Current Payout to Shareholders

Dividends paid are well covered by earnings (2.9x coverage).


Future Payout to Shareholders

Dividends after 3 years are expected to be well covered by earnings (4.3x coverage).


Next Steps

Management

What is the CEO of UCB's salary, the management and board of directors tenure and is there insider trading?

4.5yrs

Average management tenure


CEO

Jean-Christophe Tellier (60yo)

4.7yrs

Tenure

€76,000

Compensation

Mr. Jean-Christophe Tellier has been the Chief Executive Officer and Executive Director of UCB SA since January 1, 2015 and April 24, 2014 respectively. Mr. Tellier served as an Executive Vice President at ...


CEO Compensation Analysis

Jean-Christophe's remuneration is lower than average for companies of similar size in Belgium.

Jean-Christophe's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

4.5yrs

Average Tenure

58yo

Average Age

The tenure for the UCB management team is about average.


Board Age and Tenure

5.4yrs

Average Tenure

69yo

Average Age

The tenure for the UCB board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Detlef Thielgen (59yo)

    CFO & Executive VP

    • Tenure: 11.8yrs
  • Dhaval Patel (58yo)

    Executive VP & Chief Scientific Officer

    • Tenure: 1.9yrs
  • Bharat Tewarie (58yo)

    Chief Marketing Officer & Executive VP

    • Tenure: 4.5yrs
  • Charl Van Zyl (52yo)

    COO & Executive Vice President

    • Tenure: 2.5yrs
  • Pascale Richetta (60yo)

    Head of Bone Disorders Patient Value Unit & Executive VP

    • Tenure: 3.6yrs
  • Iris Löw-Friedrich (59yo)

    Chief Medical Officer

    • Tenure: 11.5yrs
  • Jean-Christophe Tellier (60yo)

    CEO & Executive Director

    • Tenure: 4.7yrs
    • Compensation: €76.00k
  • Emmanuel Caeymaex (50yo)

    Executive VP & Head of Immunology Patient Value Unit

    • Tenure: 4.6yrs
  • Jeff Wren (56yo)

    Executive VP & Head of Neurology Patient Value Unit

    • Tenure: 4.6yrs
  • Jean-Luc Fleurial (54yo)

    Executive VP & Chief Talent Officer

    • Tenure: 2yrs

Board Members

  • Gerhard Mayr (73yo)

    Honorary Chairman

    • Tenure: 0yrs
    • Compensation: €70.00k
  • Mark Eyskens

    Honorary Chairman

    • Tenure: 14.7yrs
    • Compensation: €15.50k
  • Daniel Janssen (83yo)

    Honorary Deputy Chairman

    • Tenure: 0yrs
    • Compensation: €28.50k
  • Bert De Graeve (64yo)

    Independent Director

    • Tenure: 9.4yrs
    • Compensation: €106.00k
  • Georges Jacobs Hagen (79yo)

    Honorary Chairman

    • Tenure: 0yrs
    • Compensation: €30.00k
  • Evelyn de Bergendal (69yo)

    Chairman

    • Tenure: 2.3yrs
    • Compensation: €230.00k
  • Karel Boone (76yo)

    Honorary Chairman

    • Tenure: 0yrs
    • Compensation: €49.00k
  • Jean-Christophe Tellier (60yo)

    CEO & Executive Director

    • Tenure: 4.7yrs
    • Compensation: €76.00k
  • Kay Davies (68yo)

    Independent Director

    • Tenure: 5.4yrs
    • Compensation: €121.00k
  • Pierre Gurdjian (58yo)

    Vice Chairman

    • Tenure: 2.3yrs
    • Compensation: €129.00k

Company Information

UCB SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: UCB SA
  • Ticker: UCB
  • Exchange: ENXTBR
  • Founded: 1928
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €12.210b
  • Shares outstanding: 188.37m
  • Website: https://www.ucb.com

Number of Employees


Location

  • UCB SA
  • Allée de la Recherche, 60
  • Brussels
  • Brussels
  • 1070
  • Belgium

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
UCBJ.FOTCPK (Pink Sheets LLC)YesCommon SharesUSUSDJan 1980
UNCDB (Deutsche Boerse AG)YesCommon SharesDEEURJan 1980
UCBENXTBR (Euronext Brussels)YesCommon SharesBEEURJan 1980
0NZTLSE (London Stock Exchange)YesCommon SharesGBEURJan 1980
UCBBBATS-CHIXE (BATS 'Chi-X Europe')YesCommon SharesGBEURJan 1980
UCBWBAG (Wiener Boerse AG)YesCommon SharesATEURJan 1980
UCBJ.YOTCPK (Pink Sheets LLC)UNSPONSORED ADRUSUSDFeb 2009

Biography

UCB SA, a biopharmaceutical company, researches, develops, manufactures, sells, and distributes biopharmaceutical solutions for people living with neurology and immunology conditions. The company’s core pr ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/09/19 20:41
End of Day Share Price2019/09/19 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.